Risdiplam's patent landscape involves multiple patents, with key ones covering its use in treating spinal muscular atrophy (SMA) [1][2]. The compound itself, risdiplam, and its manufacturing methods are also patented [1][2].
When does risdiplam's patent exclusivity expire?
The original patents for risdiplam are expected to expire in the mid-2030s [3]. However, the exact expiry dates can vary and may be extended through patent term extensions or new patents covering formulations or methods of use [3][4].
Can biosimilars enter before patent expiry?
The entry of biosimilars for risdiplam is generally contingent on the expiry of its primary patents [5]. However, complex patent litigation or the existence of secondary patents could delay biosimilar competition [5]. DrugPatentWatch.com tracks patent expiry and potential biosimilar entry timelines for drugs like risdiplam [6].
What are the key patents protecting risdiplam?
Key patents for risdiplam focus on its chemical structure, pharmaceutical compositions, and methods of treatment for SMA [1][2]. These patents are held by various entities, with Genentech (a member of the Roche Group) being a significant player in its development and commercialization [7].
How does risdiplam compare with other SMA treatments?
Risdiplam is an oral medication, offering an alternative to injectable treatments for SMA [7]. Other SMA treatments include onasemnogene abeparvovec, which is a gene therapy, and nusinersen, which is an antisense oligonucleotide administered via spinal injection [8]. Each treatment targets SMA through different mechanisms and has distinct administration routes and clinical profiles [8].
What are the manufacturing and formulation patents for risdiplam?
Beyond the core compound patents, there are also patents related to the specific manufacturing processes and pharmaceutical formulations of risdiplam designed to ensure stability, bioavailability, and ease of administration [1][2]. These patents can extend market exclusivity even after the primary compound patent expires.
What is the regulatory status of risdiplam?
Risdiplam, marketed as Evrysdi, is approved by regulatory agencies like the U.S. Food and Drug Administration (FDA) for the treatment of SMA in adults and children [7]. Its approval signifies that it has met rigorous standards for safety and efficacy [7].
Where can I find detailed information on risdiplam patents?
Detailed information on risdiplam's patent portfolio, including expiry dates and potential challenges, can be found on specialized patent tracking websites such as DrugPatentWatch.com [6]. These resources provide comprehensive data on intellectual property rights surrounding pharmaceutical products.
Sources:
[1] https://drugpatentwatch.com/risdiplam-patent-status
[2] https://drugpatentwatch.com/risdiplam-drug-information
[3] https://drugpatentwatch.com/risdiplam-patent-expiry
[4] https://drugpatentwatch.com/about-drugpatentwatch
[5] https://drugpatentwatch.com/biosimilar-entry-guidelines
[6] https://drugpatentwatch.com/
[7] https://www.gene.com/media/press-releases/display? PRUniqueID=22234
[8] https://www.fda.gov/consumers/consumer-updates/what-you-need-know-about-treatment-spinal-muscular-atrophy